Germany's Wilex has long been on the way out of biotech, but a new collaboration with Roche provides the company with some cash up front and a shot at down-the-line royalties.
While Atlas Venture was busy putting together a syndicate for Raze in Cambridge, MA, the venture group was also engaged in hatching a $32 million round across the Atlantic in the scientific hotbed of Cambridge, U.K. Atlas partnered with SV Life Sciences and three corporate venture arms--Novartis Venture Fund, GlaxoSmithKline's SR One and Astellas Venture Management--to back Bicycle Therapeutics.
Atlas Venture is launching one of its newly built biotechs with a Series A of $24 million, a founding partner on the board, a pair of its entrepreneurs heading the crew and some marquee investors in the syndicate, which includes Novartis. They've begun a voyage of discovery with Raze Therapeutics, part of Atlas's growing fleet of startups, to see how far they can go down a pathway that offers its investigators a shot at throwing a monkey wrench into the metabolic processes cancer uses to thrive.
Eisai and partner Helsinn secured the FDA's blessing to market Akynzeo, a combination treatment designed to prevent nasuea and vomiting among cancer patients undergoing chemotherapy.
Alnylam's in-development RNAi treatment successfully staved off nerve damage related to a rare disease in an ongoing study, the biotech said, early but promising results as the company heads into Phase III with partner Sanofi in tow.
Massachusetts General Hospital investigator Rudy Tanzi has created a new "Alzheimer's-in-a-dish" approach to growing brain cells that he claims provides clear proof of the much-debated amyloid hypothesis as well as a solid target for the disease. And now he reportedly plans to race ahead with his new research process to find a potential megablockbuster drug that can stop the disease in its tracks.
Pfizer has picked up a priority review designation for its closely watched cancer drug palbociclib, potentially slicing four months off the review timeline for a therapy that is being hustled along at an accelerated rate.
Last spring a prominent analyst suggested that a successful late-stage study for Smith & Nephew's spray-on cell therapy for wound healing could be a catalyst to break up the company a la Abbott and Baxter. But today, the discussion of the much buzzed-about trigger event turned bitter after the company reported that the Phase III trial flopped.
Gilead Sciences picked up a much-anticipated FDA approval for Harvoni, a combination therapy for hepatitis C that promises to cure the majority of patients without the need for painful injections that have plagued patients for years.
Novartis has expanded its relationship with the U.K.'s Oxford BioMedica, signing a deal worth up to $90 million that will support the drugmaker's efforts in CAR-T immunotherapies.
Prosensa has begun the FDA submission process for its treatment for Duchenne muscular dystrophy, planning to fully file by year's end with hopes of finally winning approval for a drug that has survived a few brushes with failure.
Isis Pharmaceuticals has kicked off a Phase III trial on ISIS-SMNrx, a treatment for the rare spinal muscular atrophy, moving forward with the orphan drug as partner Biogen Idec considers whether to take the plunge on the program.
David Mazzo is out at Regado Biosciences, resigning from the CEO post as the company he led into Phase III works to move on from a disastrous clinical roadblock.
Amgen is angling for an early FDA nod for the leukemia treatment blinatumomab, racing to market with what the company hopes will be the first of many cancer therapies derived from its proprietary T cell platform.
After 9 years of fruitless work on treatments for Alzheimer's disease and depression, AstraZeneca is dissolving its partnership with Targacept, leaving the battered biotech to pick up the pieces of its dwindling pipeline.
Famed corporate raider Carl Icahn is taking his agitating to Tumblr, from now on posting his musings in the realm of cat GIFs, teenage fan fiction and some questionable respect for intellectual property.
After acknowledging a midstage setback for its key respiratory drug benralizumab in COPD last month, AstraZeneca's big MedImmune division has come back with positive, though somewhat mixed, Phase IIb data underscoring the effectiveness of knocking down eosinophils--white blood cells--in preventing asthma attacks.
Welcome to the latest edition of our weekly EuroBiotech Report.